Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, 28-day, randomized, parallel-group, open-label study evaluating the efficacy and safety of twice daily oral doses of testosterone (150-400mg) co-administered with 0.25mg dutasteride compared with 400mg testosterone alone and 0.25mg dutasteride alone in the treatment of hypogonadism.

Next Previous
X
Search
Trial Profile

A phase II, 28-day, randomized, parallel-group, open-label study evaluating the efficacy and safety of twice daily oral doses of testosterone (150-400mg) co-administered with 0.25mg dutasteride compared with 400mg testosterone alone and 0.25mg dutasteride alone in the treatment of hypogonadism.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dutasteride/testosterone (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors GSK

    • Most Recent Events

    • 13 Jun 2009 Results presented at the 91st Annual Meeting of the Endocrine Society
    • 12 Oct 2008 Status changed from discontinued to completed.
    • 30 Jan 2008 Status changed from in progress to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top